Fairfield, CT – May 25 2016 – Calmare Therapeutics Incorporated, (OTC: CTTC) (CTI), the pain mitigation company, will present at the 5th Annual SeeThruEquity Microcap Investor Conference at Convene on 730 Third Avenue in New York City on May 31, 2016.
"This is a great venue to share the Calmare story," said CTI President & CEO Conrad Mir. "And we are thankful for being given the opportunity to present."
About the Conference
Presenting companies will be provided with a 30-minute time slot to present to an audience of investors and industry professionals. Company management will also be available for one-on-one meetings with institutional investors. Please click here for a list of presenting companies.
Conference registration is complimentary for qualified investors and equity research analysts.
In order to register as an attendee of the conference, please click HERE.
Since its founding in 2011, SeeThruEquity (STE) has been committed to its core mission: providing impactful, high quality research on uncovered and under-covered microcap stocks and hosting investor conferences throughout the year. STE has been able to grow its research universe to over 190 names. STE conferences are the ultimate event for publicly traded companies with less than $1 billion in market capitalization because it augments the conference experience with the firm's research which is part of Wall Street consensus and available across industry leading platforms including Thomson First Call, FactSet, S&P CapitalIQ, Yahoo! Finance and Bloomberg to name a select few. STE has hosted 20 investor conferences which have showcased over 350 companies, attracted over 4500 attendees and have included over 1,700 1-on-1 meetings. For more information please visit www.steconference.com.
About the Company
Calmare Therapeutics Incorporated, the Calmare Pain Mitigation Therapy™ company, researches, develops and commercializes chronic, neuropathic pain and wound affliction devices. Our flagship medical device - the Calmare® Pain Therapy Device - is the world's only non-invasive and non-addictive modality that can successfully treat chronic, neuropathic pain. The Company holds a U.S. Food & Drug Administration 510k clearance designation (K081255) on its flagship device, which grants it the exclusive right to sell, market, research and develop the medical device in the United. Calmare Devices are commercially sold to medical practices throughout the world. They are also found in U.S. military hospitals, clinics and on installations via CTI’s General Services Administration (GSA) military contract (V797P-4300B).
Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company’s current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.